Mersana Therapeutics Held Q2 2024 Conference Call

CAMBRIDGE, Mass., Aug. 06, 2024 – Mersana Therapeutics, Inc. (NASDAQ: MRSN), a biopharmaceutical company in the clinical stage, is dedicated to the discovery and development of antibody-drug conjugates (ADCs) aimed at treating cancers with significant unmet medical needs. The company had announced that it would release its business updates and financial results for the second quarter ending June 30, 2024, on Tuesday, August 13, 2024. In conjunction with this, Mersana had hosted a conference call and webcast at 8:00 a.m. Eastern Time on the same day. Interested parties were able to access the call by dialing 833-255-2826 for domestic calls or 412-317-0689 for international calls. Additionally, a live webcast of the presentation was available on the Investors & Media section of the Mersana website. A replay of the webcast was also accessible on the website for approximately 90 days following the event.

Mersana Therapeutics is a company in the clinical stage that focuses on creating innovative ADCs. These ADCs are intended to provide new treatment options for cancer patients who currently have limited choices. The company has developed proprietary platforms for ADCs, named Dolasynthen and Immunosynthen, which are designed to produce both wholly-owned and partnered product candidates. These candidates have the potential to treat various types of cancers.

The pipeline of Mersana Therapeutics includes promising candidates such as XMT-1660 and XMT-2056. XMT-1660 is an ADC developed using the Dolasynthen platform and targets B7-H4, a protein often overexpressed in certain cancers. On the other hand, XMT-2056 is created using the Immunosynthen platform and targets a novel epitope of the human epidermal growth factor receptor 2 (HER2), which is a critical protein involved in the growth of some cancer cells.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!